Publication:
Follow-up of patients with epilepsy harboring antiglycine receptor antibodies

Placeholder

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Ekizoğlu, Esme
Baykan, Betül
Sezgin, Mine
Erdağ, Ece
Gündoğdu-Ünverengil, Gökçen
Tektürk, Pınar
Yılmaz, Ebru
Bebek, Nerses
Tüzün, Erdem

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Objective: The long-term follow-up of patients with epilepsy harboring autoantibodies against the glycine receptor (also glycine receptor antibodies or GlyR-Ab) is not well-known. Our aim was to investigate the 5-year prognosis and treatment response of patients with epilepsy who were seropositive for GlyR-Ab. Methods: Clinical features; electroencephalogram (EEG), neuroradiological, and neuropathological findings; and treatment responses of patients with epilepsy with GlyR-Ab seropositivity were investigated. Results: Thirteen (5.46%) of 238 patients with epilepsy were GlyR-Ab positive: focal epilepsy of unknown cause (FEoUC) was diagnosed in four (7.27%) out of 55 patients, mesial temporal lobe epilepsy with hippocampal sderosis (MTLE-HS) in five (4.5%) out of 111 patients, epileptic encephalopathy (EE) in two (4%) out of 50 patients, and status epilepticus (SE) in two (9.09%) out of 22 patients. None of the patients developed any other neurological symptoms or cancer during the 5-year follow-up. Seven of them had seizures that were resistant to antiepileptic drug (AED). Immunotherapy was used in two patients (with FEoUC and EE) improving seizure control. Three patients with MTLE-HS benefited from epilepsy surgery, and another patient with EE showed spontaneous remission. Conclusion: Glycine receptor antibodies are detected in a wide spectrum of epileptic disorders with undear pathogenic significance. Two GlyR-Ab seroposilive patients with AED-resistant epilepsy treated with intravenous immunoglobulin (Mg) showed dear benefit from immunotherapy. Future studies will be valuable in determining the role of screening patients with drug-resistant epilepsy for GlyR-Ab in order to identify patients who may benefit or respond to immunotherapy.

Source

Publisher

Elsevier

Subject

Psychology, Clinical neuropsychology, Psychiatry

Citation

Has Part

Source

Epilepsy and Behavior

Book Series Title

Edition

DOI

10.1016/j.yebeh.2018.09.034

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details